Abstract 517P
Background
The prognostic predictive value of breast cancer susceptibility gene 1 (BRCA1) for non-small-cell lung cancer (NSCLC) remains controversial. This study aimed to determine the prognostic effect of BRCA1 on NSCLC survival using meta-bioinformatic analysis.
Methods
Candidate articles were identified from PubMed, Embase, Cochrane Library, and Web of Science databases. Effect measures generated were the pooled hazard ratio (HR) and 95% confidence interval (CI). Cox regression model was performed in an independent dataset from TCGA to validate the accuracy of our meta-analysis.
Results
A total of 2462 patients from 15 studies of acceptable quality were included. No significant differences in overall survival (OS)/cancer-specific survival (CSS) (HR = 1.38, 95% CI: 0.95-2.00, P = 0.094) or progression-free survival (PFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 1.28, 95% CI: 0.82-2.00, P = 0.284) were observed between patients with high- and low-expression of BRCA1. However, patients with lung adenocarcinoma (LUAD) and increased BRCA1 expression had markedly poorer OS/CSS (HR = 1.78, 95% CI: 1.05-3.03, P = 0.032) than those with reduced BRCA1. Bioinformatics analysis also indicated that BRCA1 overexpression was independently correlated with decreased OS in LUAD. Moreover, patients with high BRCA1 were more likely to suffer from lymph node metastasis than those with low BRCA1.
Conclusions
Elevated BRCA1 expression may be a novel biomarker of poor OS for patients with LUAD.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract